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Abstract 1 
Rationale: Data from animal models of hypertension indicate that high blood pressure may 2 
develop as a vital mechanism to maintain adequate blood flow to the brain. We propose that 3 
congenital vascular abnormalities of the posterior cerebral circulation and cerebral 4 
hypoperfusion could partially explain the etiology of essential hypertension, which remains 5 
enigmatic in 95% of patients.  6 
 7 
Objective: To evaluate the role of the cerebral circulation in the pathophysiology of 8 
hypertension. 9 
 10 
Methods and Results: We completed a series of retrospective and mechanistic case-control 11 
magnetic resonance imaging and physiological studies, in normotensive and hypertensive 12 
humans (n=259). Interestingly, in humans with hypertension, we report a higher prevalence of 13 
congenital cerebrovascular variants; vertebral artery hypoplasia and an incomplete posterior 14 
circle of Willis, which were coupled with increased cerebral vascular resistance, reduced 15 
cerebral blood flow and a higher incidence of lacunar type infarcts. Causally, cerebral vascular 16 
resistance was elevated before the onset of hypertension and elevated sympathetic nerve 17 
activity (n=126). Interestingly, untreated hypertensive patients (n=20) had a cerebral blood flow 18 
similar to age-matched controls (n=28). However, participants receiving anti-hypertensive 19 
therapy (with blood pressure controlled below target levels) had reduced cerebral perfusion 20 
(n=19). Finally, elevated cerebral vascular resistance was a predictor of hypertension 21 
suggesting it may be a novel prognostic and/or diagnostic marker (n=126).   22 
 23 
Conclusions: Our data indicate that congenital cerebrovascular variants in the posterior 24 
circulation and the associated cerebral hypoperfusion may be a factor in triggering 25 
hypertension. Therefore lowering blood pressure may worsen cerebral perfusion in susceptible 26 
individuals.  27 
 28 
 29 
Key words: Hypertension, vertebral artery hypoplasia, cerebral blood flow, sympathetic nerve 30 
activity, and magnetic resonance imaging  31 
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Abbreviations 1 
 2 
ANCOVA; analysis of covariance 3 
BMI; body mass index 4 
BOLD; blood oxygen level dependant 5 
BP; blood pressure 6 
DBP; diastolic blood pressure 7 
CoW; circle of Willis 8 
MRI; magnetic resonance imaging 9 
MRA; magnetic resonance angiography 10 
MSNA; Muscle sympathetic nerve activity 11 
NHS; National Health Service 12 
SBP; systolic blood pressure 13 
SNA; sympathetic nerve activity 14 
PCASL; pseudo continuous arterial spin labelling 15 
RVLM; rostral ventrolateral medulla 16 
TE; echo time 17 
TR; repetition time 18 
VAH; vertebral artery hypoplasia 19 
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Introduction 1 
High blood pressure (blood pressure) affects ~25% of the world’s population and is the largest 2 
single contributor to global mortality 1. Hypertension represents a significant economic burden to 3 
public healthcare providers, where the global cost of non-optimal BP is estimated to be US$370 4 
billion (10% of healthcare expenditure) 2. Remarkably, despite the availability of many 5 
pharmacological treatments, BP is poorly controlled with a recent report stating that only 53% of 6 
patients prescribed anti-hypertensive medication have BP controlled 3. This reflects the well-7 
known heterogeneity of the syndrome including epigenetic and inherited factors contributing to 8 
the unknown causes in 95% of patients 4.  9 
 10 
Despite the devastating consequences of hypertension (e.g. stroke, kidney failure, coronary 11 
heart disease, death 1, 2), the mechanisms that lead to the onset of hypertension in humans are 12 
poorly understood. It is well established that elevated sympathetic nerve activity (SNA) 13 
contributes to the development of hypertension in most humans 5-7 but what initiates this 14 
remains unclear. Experimental data from hypertensive rats and observations in post-mortem 15 
human studies suggest that blood flow to the brain might be important in setting the operating 16 
level of SNA and thus systemic arterial pressure 8, 9.   Evidence from Dickinson 10 showed that 17 
the vertebral arteries in hypertensive patients were narrower than those observed in 18 
normotensive individuals. Dickinson and Thomson 9 demonstrated that high vertebral artery 19 
resistance correlated with higher blood pressure; importantly, a weaker relationship was found 20 
in other arteries including femoral, renal and internal carotid arteries. They proposed that 21 
narrowing of the vertebral arteries with subsequent brainstem hypoperfusion might be a cause 22 
of hypertension, rather than being a consequence, but had no evidence to support causality. 23 
This has been termed “Cushing’s mechanism” or “the selfish brain hypothesis” of hypertension 24 
11
. The mechanism may trigger elevations in SNA and BP thereby maintaining cerebral blood 25 
flow 8, 12. Evidence from spontaneously hypertensive rats at a pre-hypertensive age supports 26 
this notion: Cates et al. 8 demonstrated that vertebrobasilar artery hypertrophy occurred before 27 
the onset of hypertension in these animals. The authors also showed that brainstem ischemia 28 
caused by bilateral vertebral artery clamping, generated a greater increase in SNA in pre-29 
hypertensive spontaneously hypertensive rats compared to age-matched normotensive 30 
animals8. Additionally, the brainstem of hypertensive rats is hypoxic and this is accentuated 31 
when BP is normalised 13.  32 
 33 
We have addressed the issue of whether “Cushing’s mechanism” is involved in the development 34 
of hypertension in humans. This may have a significant impact on the diagnosis and treatment 35 
of hypertension, whilst potentially aiding prevention of early onset vascular dementia in 36 
hypertensive humans14. Thus, we have evaluated the temporal relationship of changes in 37 
cerebral vascular structure and cerebral blood flow with both the onset of hypertension and 38 
raised SNA in humans. We performed a series of retrospective and mechanistic case-control 39 
studies in a range of participants with different levels of BP and classifications of hypertension.  40 
Uniquely, we show that congenital cerebral vascular variants, vascular resistance and blood 41 
flow are tightly coupled to the development of hypertension in humans.  42 
 43 
Methods 44 
Retrospective study 45 
We first measured whether there were anatomical differences in the cerebral circulation of 46 
hypertensive patients compared to controls. We specifically focused on vertebral artery 47 
hypoplasia (VAH; a congenital anatomical variant of the posterior circulation that occurs in the 48 
general population), which is associated with lower posterior cerebral territory blood flow 15, and 49 
variations in the anatomy of the circle of Willis (CoW). We hypothesised that the occurrence of 50 
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anatomical variants in the vertebral arteries and CoW would be higher in the hypertensive 1 
population compared to that reported for healthy controls.  2 
 3 
Study population 4 
133 patients with essential hypertension referred to the Bristol Heart Institute tertiary 5 
hypertension clinic between February 2012 and April 2015 were included in the retrospective 6 
analyses (secondary causes of hypertension had been excluded in clinic). The local Research 7 
Ethics committee confirmed that the study conformed to the governance arrangements for 8 
research ethics committees. All patients provided written informed consent. Supplementary 9 
Table 1 shows patient characteristics. Cases included were from consecutive referrals by the 10 
hypertension clinic to the Cardiovascular Magnetic Resonance Unit in the NIHR Bristol 11 
Cardiovascular Biomedical Research Unit in the Bristol Heart Institute.  12 
 13 
BP measurements 14 
Average office systolic (SBP) and diastolic BP  (DBP) were measured from both arms after 15 
seated rest, using standard automated sphygmomanometry with an appropriate sized cuff 16. In 16 
a subgroup of patients (n= 84), 24 hour ambulatory BP monitoring was completed 17 17 
(Supplementary Table 1).  18 
 19 
MRI procedures 20 
3D time-of-flight MR angiography (MRA) at 1.5T (Avanto, Siemens, Erlangen, Germany) with a 21 
dedicated head coil was used to measure arterial anatomy (TR = 38ms, TE= 5.28ms, flip angle 22 
= 25 degrees, voxel size = 0.7 x 0.5 x 0.8mm, field of view = 200mm, covering major arteries 23 
feeding into the CoW). See supplementary material for further information regarding angiogram 24 
analyses.  25 
 26 
Briefly, vertebral artery hypoplasia (VAH) was defined as a diameter <2 mm uniformly 27 
throughout the vessel 15. Anterior and posterior CoW anatomy was reviewed as previously 28 
described 18. VAH was compared to data previously reported from 306 healthy controls 15. CoW 29 
morphology was classified according to normal reference standards 18.  30 
 31 
Case-control study 32 
Participants 33 
Following approval by NHS Research Ethics Committee (11/SW/0207) and local R&D approval, 34 
142 participants were prospectively recruited and enrolled at a single site (University Hospitals 35 
Bristol NHS Foundation Trust). Participants gave their written informed consent to participate in 36 
this study. 16 volunteers were excluded due to screen failure and/or early termination of MRI 37 
scan due to discomfort or unforeseen technical difficulties. See supplementary material for 38 
inclusion and exclusion criteria. Table 1 outlines participant characteristics and the number and 39 
classes of anti-hypertensive medications being taken.  One patient in this study had received 40 
renal denervation, which was successful in treating their hypertension. 41 
 42 
Six specific BP subgroups were prospectively recruited: young normotensive (age <35 years; 43 
Table 2 for characteristics), older normotensive (age >35 years), borderline/pre-hypertensive, 44 
untreated hypertensive, treated-controlled hypertensive (taking anti-hypertensive medication 45 
and BP controlled), and treated-uncontrolled hypertensive groups (taking anti-hypertensive 46 
medications, but BP uncontrolled). Borderline hypertension was defined as an office BP 135-47 
140/85-90 mmHg and a daytime ambulatory BP 130-135/80-85 mmHg.  48 
 49 
Screening BP  50 
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Participants attended a screening session, where office BP was measured using an automated 1 
cuff (Omron, The Netherlands), in line with the European Society of Hypertension guidelines 19. 2 
Participants were fitted with an ambulatory BP monitor (Spacelabs, OSI Systems Company, 3 
USA). Their 24-hour BP was measured twice per hour during the daytime and once per hour 4 
during the night.  5 
 6 
Microneurography 7 
Peroneal microneurography was completed to measure multi-unit muscle sympathetic nerve 8 
activity (MSNA). For full methods, see supplementary material. Following instrumentation, 5-10 9 
minutes of baseline data were collected in all patients. Heart rate, BP and MSNA were 10 
measured and recorded continuously using a data acquisition program on a study laptop 11 
(LabChart, AD instruments).  12 
 13 
MRI acquisition 14 
All study participants were scanned using 3T MRI (GE HDx, Milwaukee, Wisconsin, USA).  The 15 
protocol consisted of a high resolution T1-weighted fast spoiled gradient echo (3D-FSPGR) 16 
structural scan, 3D time of flight angiography to measure arterial anatomy, phase contrast pulse 17 
sequences to measure blood flow in the internal carotid and basilar arteries at baseline and in 18 
response to 5% CO2, and pseudo-continuous arterial spin labelling (PCASL) to measure 19 
regional cerebral blood flow. BP (automated cuff), heart rate (pulse oximeter), and end tidal CO2 20 
(capnograph) were monitored throughout all acquisitions. See supplementary information for 21 
imaging parameters.  22 
 23 
Since poor cerebral vascular reactivity is linked to the risk of developing hypertension, we 24 
hypothesised that the hypertensive group would have impaired cerebral vascular reactivity. In a 25 
subgroup of participants, cerebral vascular reactivity to isoxic hypercapnia (5% CO2) and to a 26 
strong visual stimulus (flashing checkerboard20,  using a dual echo blood oxygen level 27 
dependent; BOLD and ASL MRI acquisition) was measured (supplementary material for MRI 28 
parameters). 29 
 30 
MRI analyses 31 
All data analyses were blinded and completed by separate investigators. Please see 32 
supplementary material for details regarding methodology for MRI analyses. In short, to 33 
measure blood flow in the right and left internal carotid and basilar arteries, phase contrast 34 
images were analysed using Segment (version 1.9, Medviso, Sweden)21.  Total cerebral blood 35 
flow was estimated as the sum of blood flow in these vessels and scaled for parenchymal tissue 36 
volumes. Cerebral vascular resistance was calculated as the brachial mean arterial pressure 37 
(measured during the phase contrast acquisition) divided by average flow in each vessel. This 38 
method assumes that intra-cranial pressure and venous pressure is normal and similar between 39 
groups, and therefore that mean arterial pressure is an accurate estimation of cerebral perfusion 40 
pressure in different groups. The method has been used in multiple studies to calculate cerebral 41 
vascular resistance 22, 23. Regional cerebral perfusion was measured from the PCASL images 42 
using the standard Buxton model 24. Cerebral vascular reactivity to hypercapnia (5% CO2) was 43 
calculated as the change in total cerebral blood flow (calculated as the sum of blood flow in the 44 
internal carotid and basilar arteries, measured using phase contrast MRI) from the normocapnic 45 
condition. Blood flow was scaled for changes in end tidal CO2 and blood pressure. Finally, 46 
positive and negative changes in cerebral blood flow and BOLD signal, in response to the 47 
flashing checkerboard stimulus, were measured in the visual cortex.  48 
 49 
Statistical analyses 50 
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All data analysis was blinded. An unpaired Students T-test was used to test for differences in 1 
participant’s characteristics/demographics between normotensive and hypertensive groups. A 2 
one-way ANCOVA was used to test for differences in total cerebral blood flow, regional cerebral 3 
blood flow and MSNA between hypertensive and normotensive groups, using BMI as a 4 
covariate.   Binary logistic regression (enter method) was used to test for differences in the 5 
prevalence of anatomical variations (VAH, incomplete posterior CoW or VAH with an incomplete 6 
posterior CoW) between hypertensive and normotensive groups. To test for differences in 7 
cerebral blood flow and cerebral vascular resistance, between hypertensive and normotensive 8 
participants with and without anatomical variants, a one-way ANCOVA (BMI as a covariate) was 9 
used with a Bonferroni test for multiple comparisons. Participants sub-grouped into specific 10 
normotensive and hypertensive groups; a one-way ANCOVA (BMI as covariate) with a 11 
Bonferroni test for multiple comparisons was used to test for differences in demographics, BP , 12 
cerebral blood flow, cerebral vascular resistance and MSNA.  13 
 14 
To predict which variables might be better predictors of hypertension (i.e. is cerebral vascular 15 
resistance a stronger predictor of hypertension than BMI?), conditional forward binary logistic 16 
regression was completed, where diagnosis of hypertension was the dependent variable. The 17 
independent variables were age, BMI, cerebral blood flow, cerebral vascular resistance, VAH 18 
plus an incomplete posterior CoW and MSNA. All statistical tests were two-tailed. Alpha was set 19 
at 0.05.  Where appropriate data are reported as mean ± SEM, median with interquartile range 20 
or as percentage with 95% confidence intervals. 21 
 22 
Results 23 
Retrospective study 24 
Anatomical variations in the cerebral vasculature 25 
Patient characteristics are outlined in the Supplementary Table 1.  Fishers exact test showed 26 
that VAH and an incomplete posterior CoW were highly prevalent in the hypertensive population 27 
(hypertensive vs. normotensive15, 18: 53% vs. 27% and 64% vs. 36% respectively; P<0.0001, 28 
Figure 1). The odds ratios indicated that individuals with VAH or those with an incomplete 29 
posterior CoW were 2.8 (95% CI; 1.8 to 4.3) and 3.1 (95% CI; 1.6 to 6.1) times more likely to 30 
have hypertension. There were no differences in the prevalence of an incomplete anterior CoW 31 
between our hypertensive cohort and that reported in a healthy control population18 (32% vs. 32 
25%, respectively, P=0.26). 33 
 34 
During the retrospective analysis we noted that there was also a high prevalence of VAH with 35 
an incomplete posterior CoW (27%). The prevalence of having both variants has not been 36 
compared in healthy controls previously. We were interested in whether the prevalence was 37 
higher in the hypertensive patients compared to controls, since having both may present further 38 
challenges to perfuse the posterior regions of the brain. These results prompted a case-control 39 
study where we assessed whether the anatomical variations in the posterior cerebral 40 
vasculature related functionally to differences in cerebral perfusion and vascular resistance in 41 
hypertensive patients 42 
 43 
Case-control study 44 
Participant characteristics  45 
The hypertensive (n=77) and normotensive groups (n=49) were similar in age and height 46 
(P=0.12); however, body mass index (BMI) and body mass were lower in the normotensive 47 
group (P=0.02, Students T-test, Table 1). Office BP, day-/night-time ambulatory BP and MSNA 48 
were higher in the hypertensive compared to the normotensive group (P<0.0001, ANCOVA, 49 
Table 1). Hypertensive patients had a higher incidence of lacunar infarcts (14%) compared to 50 
normotensive patients (4%, P=0.03), but the number of subcortical and cortical infarcts were 51 
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similar between groups (3% vs. 2%; P=0.680, and 1% vs. 1%; P=0.831, respectively, Fishers 1 
Exact Test). 2 
 3 
Anatomical variants in the posterior cerebral vasculature are more prevalent in humans with 4 
hypertension 5 
We observed that VAH, an incomplete posterior CoW and VAH with an incomplete posterior 6 
CoW were higher in hypertensive (57%, 60%, and 42%; analysed using MR angiography by 7 
blinded radiologist) compared to normotensive participants (Figure 1; 30%; P=0.006, 37%; 8 
P=0.028 and 19%; P=0.006; respectively, binary logistic regression; enter method). The odds 9 
ratio indicated that if VAH, an incomplete posterior CoW or VAH with an incomplete posterior 10 
CoW were present, then individuals were 3.0 (95% CI: 1.4 – 6.3), 2.6 (95% CI: 1.2 – 5.6) and 11 
3.2 (95% CI: 1.4-7.6) times more likely to have hypertension, respectively. Conditional forward 12 
binary logistic regression selected VAH as the strongest predictor of having a diagnosis of 13 
hypertension, when both VAH and an incomplete posterior CoW were inserted into the model 14 
(odds ratio= 2.8; 95% CI: 1.2-6.2, P=0.017 vs. odds ratio 2.5; 95% CI: 1.1-5.6, P=0.020) 15 
respectively). Importantly, there was no difference in the prevalence of an incomplete anterior 16 
CoW between hypertensive (25%) and normotensive (32%) groups (P=0.46).  Missing anterior 17 
communicating arteries were the main cause of an incomplete anterior CoW. The A1 segment 18 
of the anterior cerebral artery was missing in only a small proportion of individuals (left A1; 1% 19 
vs. 0%; P=1.00 and right A1; 4% vs. 7%; P=0.45 in hypertensives and normotensives 20 
respectively). There was no difference in the prevalence of a combined incomplete posterior 21 
and anterior CoW between hypertensive and normotensive groups (27% vs. 20%, P=0.35). 22 
Finally, binary logistic regression indicated that there was no interaction between BMI and VAH 23 
(β= 0.016; P=0.234) or VAH plus an incomplete CoW (β= 0.018; P=0.77).  24 
 25 
Next, we determined whether these anatomical variants in the posterior cerebral circulation are 26 
functionally important.  Total arterial cerebral blood flow (measured using MR phase-contrast 27 
imaging) was lower in the hypertensive compared to the normotensive group (Table 1, 28 
P<0.0001; ANCOVA). Using region of interest analysis on cerebral perfusion maps (PCASL), 29 
cerebral perfusion was lower in the hypertensive compared to normotensive group in all regions 30 
studied (Table 3, P<0.05; ANCOVA). Moreover, total cerebral vascular resistance was higher in 31 
hypertensive participants versus those with normotension (P<0.0001; ANCOVA, Table 1). We 32 
hypothesised that VAH and/or an incomplete posterior CoW would be associated with lower 33 
cerebral perfusion.  34 
 35 
Participants were split into those with/without VAH (n=56/68, respectively) regardless of their BP 36 
status. Those with VAH had a lower total arterial cerebral blood flow (P<0.0001, ANCOVA) and 37 
a higher cerebral vascular resistance (P<0.0001) than those without these anatomical variants 38 
(Figure 2). Data for both VAH and an incomplete posterior CoW showed similar differences and 39 
are presented in Figure 2. 40 
 41 
Interestingly, hypertensive participants with VAH (n=39) had a lower cerebral arterial blood flow 42 
compared to hypertensives without VAH (n=36; Figure 2, P=0.014, one-way ANCOVA with 43 
Bonferroni test for multiple comparisons). Additionally, the reported incidence of lacunar type 44 
infarcts was greater in hypertensive patients with VAH versus those without VAH (22% vs. 3%, 45 
P=0.001, Fishers exact test). Intriguingly, there were no differences in cerebral blood flow 46 
(P=0.750) or cerebral vascular resistance (P=0.333) between the normotensive groups with and 47 
without VAH (ANCOVA and Bonferroni post-hoc test). This suggests that: a) in normotensive 48 
individuals, VAH was not associated with a higher cerebral vascular resistance and, b) that in 49 
the presence of VAH, individuals with normal BP are able to maintain cerebral perfusion.  50 
Importantly, we found that there was no difference in total cerebral blood flow and vascular 51 
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resistance in hypertensive people with and without an incomplete anterior CoW (Supplementary 1 
Table 2). Additionally, there was no difference in these variables in hypertensives with or without 2 
both an incomplete anterior and posterior CoW (Supplementary Table 2). Similar findings are 3 
reported for the normotensive group. These data suggest that variants in the anterior CoW do 4 
not impact cerebral hemodynamics.  5 
 6 
The contralateral vertebral artery does not compensate for the hypoplastic artery in 7 
hypertensive patients 8 
Individuals with VAH usually have a larger contralateral vertebral artery, apparently 9 
compensating for the hypoplastic vessel 15. To estimate whether the contralateral vessel 10 
normalized blood flowing into the posterior circulation, we measured blood flow in the basilar 11 
artery (all data analysed with BMI as a covariate). In normotensive participants, there was no 12 
difference in blood flow in the basilar artery between those with/without VAH (11.4 ± 0.9 vs. 13.9 13 
± 0.9 mL/100mL/min, P=0.151; ANCOVA). In contrast, in the hypertensive patients there was a 14 
lower basilar blood flow with VAH compared to those without VAH (10.4 ± 0.9 vs. 13.4 ± 0.9 15 
ml/100mL/min, P=0.002). These data suggest that in participants with hypertension, the 16 
contralateral vertebral artery does not fully compensate for lower blood flow in the hypoplastic 17 
vertebral artery  18 
 19 
Assessing cause and effect: Cerebral vascular resistance, blood flow and muscle sympathetic 20 
nerve activity 21 
We next attempted to assess causality between cerebral vascular variants, cerebral 22 
hypoperfusion and the onset of elevated SNA, a driver of hypertension. To assess the temporal 23 
relationship between cerebral hypoperfusion and the onset of both increased sympathetic 24 
activity and hypertension, 4 sub-groups of patients with differing classes of hypertension were 25 
recruited and compared to age- and sex-matched normotensive controls. These groups were: 26 
borderline, untreated, treated-controlled, and treated but poorly controlled hypertensive 27 
participants (Table 2). The borderline (or high normal) group did not have hypertension but had 28 
daytime ambulatory SBP of 130-135 mmHg (Figure 3) and a high incidence of self-reported 29 
family history of hypertension in first order relatives (Table 2). The prevalence of family history 30 
of essential hypertension in all hypertensive groups was higher than that in the normotensive 31 
groups (Chi-square test, P<0.0001). Interestingly, the prevalence of VAH with an incomplete 32 
CoW was higher in the borderline hypertensive group compared to normotensive controls 33 
(borderline hypertension; 61%, and older normotension; 31%, Chi-squared test; P<0.05). 34 
 35 
Figure 3 shows that cerebral vascular resistance was elevated in the borderline hypertensive 36 
group compared to young and older normotensive controls. However, in the borderline group 37 
MSNA was not elevated and similar to the older normotensive group (49 ± 5 vs. 47 ± 3 38 
bursts/100 heart beats; ANCOVA; P=0.9). This suggests that increased cerebral vascular 39 
resistance occurs before the onset of higher MSNA and is thus a putative trigger for subsequent 40 
elevation of MSNA and blood pressure. Additionally, total cerebral blood flow was lower in the 41 
borderline hypertensive group compared to older (P=0.002) and younger normotensive groups 42 
(P=0.001), but was similar to that in the uncontrolled hypertensive (P=1.00) and treated 43 
hypertensive groups (P=1.00). The total cerebral arterial blood flow in the untreated 44 
hypertensive group was similar to that in the older (P=0.891) and younger normotensive groups 45 
(P=0.899); suggesting that in the face of higher cerebral vascular resistance, the elevated 46 
resting BP was able to normalise perfusion in this group.  47 
 48 
Is cerebral vascular resistance a good predictor of hypertension? 49 
Conditional forward binary logistic regression was completed to determine which variables were 50 
predictive of having a diagnosis of hypertension (n=126; treated controlled hypertensive group 51 
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were included in the hypertension category). Cerebral vascular resistance was the strongest 1 
predictor of a diagnosis of high BP (odds ratio 1.86, 95% CI: 1.44, 2.40, P<0.0001), followed by 2 
BMI (odds ratio 1.53, 95%CI: 1.23-1.92, P<0.0001), age (OR: 1.15, 95% CI: 1.04-1.27, 3 
P=0.009) and total cerebral blood flow (OR: 1.23, 95%CI: 1.0-1.5, P=0.01). Thus, high cerebral 4 
vascular resistance predicts hypertension.  5 
 6 
Cerebrovascular vascular reactivity, hypertension and anatomical variants 7 
We found no difference in total cerebral vascular reactivity to CO2 (expressed as per % rise in 8 
end tidal CO2 and scaled for changes in mean arterial pressure; MAP) between the 9 
hypertensive (n=29) and normotensive groups (n = 22, 5.6 ± 0.6 vs. 4.5 ± 0.7 10 
mL/100mL/min/mmHg/%; P=0.21, ANCOVA, Supplementary Figure 1). Additionally, when the 11 
groups were split into participants with (n=19) and without VAH plus an incomplete CoW (n = 12 
32; split regardless of hypertensive status), there was no difference in cerebral blood flow 13 
reactivity to CO2 (4.7 ± 0.4 vs. 5.6 ± 0.7 mL/100mL/min/mmHg/%; P=0.41, Supplementary 14 
Figure 1).  15 
 16 
We next assessed the cerebral vascular reactivity to a strong visual stimulus (Figure 4A shows 17 
example acquisition). The visual stimulus caused a similar increase in cerebral blood flow in 18 
normotensive (n=28) and hypertensive (n=36) subgroups in an activation mask within the 19 
occipital lobe, consisting of a union of significantly activated voxels in the BOLD and ASL time-20 
series (Figure 4B). In all participants, negative BOLD and cerebral blood flow signals were also 21 
detected within the occipital lobe and surrounding the visual cortex (Figure 4, panel A for 22 
example of cerebral perfusion). Despite these similar changes in blood flow, the hypertensive 23 
group exhibited a greater increase in BP during the visual stimulus (figure 4B, P=0.02, 24 
ANCOVA) suggesting that hypertensive men and women rely on increasing perfusion pressure 25 
to maintain cerebral blood flow than local vasodilatatory mechanisms. In a group with both VAH 26 
and an incomplete CoW, however, data indicated a difference in cerebrovascular reactivity. We 27 
found a blunted increase in BOLD signal along with a trend towards a blunted increase in 28 
cerebral blood flow response to the visual stimulus (Figure 4C). Moreover, linear regression 29 
analyses suggested that for participants with both VAH and an incomplete posterior CoW, the 30 
positive and negative BOLD responses have a stronger inverse relationship than for participants 31 
without VAH and incomplete posterior CoW (β1=-0.17; P<0.05 vs. β1 = 0.65; P<0.05, 32 
respectively; ANOVA, Supplementary Figure 2). This implies that for a larger positive increase 33 
in BOLD signal the hypertensive group rely on a blood flow steal from other adjacent tissue.  34 
However, this needs to be interpreted with caution since the BOLD response is a result of 35 
neurovascular coupling 25, which is a mechanism that does not solely depend on regional 36 
cerebral blood flow. 37 
 38 
Discussion 39 
This is the first confirmation in conscious humans that the cerebral vasculature and cerebral 40 
hypoperfusion might be important in the development of hypertension. This is based on: 1) a 41 
higher prevalence of congenital anatomical variants; VAH and an incomplete posterior CoW, in 42 
hypertensive patients that were associated with reduced cerebral blood flow and increased 43 
cerebral vascular resistance. 2) The association of these anatomical variants with diminished 44 
cerebrovascular reactivity in the visual cortex.  3) The finding of elevated cerebral vascular 45 
resistance before the increase in MSNA and hypertension. This was consistent with the finding 46 
that cerebral vascular resistance was found to be the greatest predictor of hypertension status 47 
compared to body mass index and age. 4) The reliance on a systemic BP surge to increase 48 
cerebral blood flow, during a visual cortex stimulus, in the hypertensive cohort. Overall, these 49 
data support our contention that, in some cases, hypertension develops as ‘self-protection for 50 
the brain’.  51 
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 1 
It is accepted that cerebral arteries and arterioles are remodelled in hypertension, thereby 2 
increasing resistance to blood flow 26. Narrowing of the vessel lumen and an increased 3 
wall/lumen ratio are typically demonstrated in animal models 8, 27, 28 and humans with 4 
hypertension 9, 29. Furthermore, cerebral blood flow is attenuated in elderly patients with 5 
hypertension 30, 31 and is related to white matter lesions32 and small vessel disease 33, a finding 6 
which is contradictory to studies indicating that cerebral autoregulation is intact in hypertensive 7 
patients 34. Our data are the first to show that in middle-aged hypertensive humans without 8 
cerebral stenotic disease, total arterial cerebral blood flow (Table 1) and cerebral perfusion in all 9 
brain regions measured (Table 3) are lower compared to age-matched normotensive 10 
participants. This may help to explain why patients with hypertension have an increased risk of 11 
developing vascular dementia 14. Traditionally, cerebral vessel remodelling and cerebral 12 
hypoperfusion were thought to be a consequence of high blood pressure. Evidence in animals 13 
and humans now suggest that this theory may be incorrect with the reverse true; cerebral artery 14 
remodelling and hypoperfusion may precede hypertension as found herein 10, 11. 15 
 16 
Remarkably, in this study, we show that cerebral vascular resistance is increased before the 17 
onset of sympathetic hyperactivity and hypertension in humans. Cerebral vascular resistance 18 
was elevated in a group of participants with borderline-high BP (daytime SBP 130-135 mmHg), 19 
as it was in all other hypertensive groups, whereas the level of SNA in the borderline population 20 
was similar to aged matched controls. A potential caveat of this study is the cross-sectional 21 
design; therefore we do not know whether the borderline hypertensive group will develop 22 
hypertension. A longitudinal study is needed to confirm this. Another potential limitation of this 23 
study is the indirect method used to calculate cerebral vascular resistance. Since measures of 24 
intracranial pressure were not possible, the method does not take into account potential 25 
variations in intracranial pressure between groups, and thus its influence on perfusion pressure 26 
and resistance. It is reasonable to assume that there was no difference in intracranial pressure 27 
between hypertensive and normotensive groups, since none of the participants showed 28 
symptoms of intracranial hypertension or hydrocephalus, and patients with tumours were 29 
removed from the study. Although many other studies have used this method of calculating 30 
cerebral vascular resistance22, 23, the method needs validating in both healthy controls and 31 
patients with disease. 32 
 33 
In the borderline hypertensive group, total arterial cerebral blood flow was lower than that in 34 
aged matched controls and the untreated hypertensive group, indicating that their BP had not 35 
corrected for the reduction in cerebral perfusion. Since these participants have a similar self-36 
reported family history to groups of hypertensive patients, they may represent a group of 37 
patients who have a high probability of developing hypertension in later life. Interestingly, the 38 
treated controlled hypertensive group had lower cerebral perfusion compared to the untreated 39 
group. This supports previous data, where anti-hypertensive treatment (except for angiotensin 40 
receptor blockers) was associated with a decline in cerebral blood flow and parenchymal tissue 41 
volumes 35. Additionally, other studies indicate that in patients with hypertension, decreased 42 
mean arterial pressure occurred concomitantly with cognitive decline and increased Tau related 43 
neuro-degeneration 36. Therefore, although BP lowering confers a reduced risk of a 44 
cardiovascular event37, it may also lower cerebral perfusion especially when cerebral artery 45 
hypoplasia and high cerebral vascular resistance exist. Our data emphasise the need to assess 46 
cerebral artery architecture and resistance to ensure that cerebral blood flow is not 47 
compromised when BP is lowered. A failure to do so may put patients at risk of developing 48 
cognitive impairment and vascular dementia.  This is critical to consider following the results of 49 
the recent SPRINT trial, where intensive BP lowering (target <120 mmHg) was shown to provide 50 
added protection against fatal and non-fatal cardiovascular events 38. Conversely, lower target 51 
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BP (<120 mmHg) was associated with adverse events, such as syncope and orthostatic 1 
intolerance. Although trials, such as the SPRINT38 and Secondary Prevention of Small 2 
Subcortical Strokes39 indicate decreased incidence stroke with lower BP targets (<120 and <130 3 
mmHg, respectively), these changes were non-significant. The long-term effect of intensive BP 4 
lowering on cognitive health and the rate of dementia has yet to be assessed. 5 
 6 
If cerebral hypoperfusion causes sympathoexcitation and hypertension then the brain must 7 
sense hypoxemia. The highly vascularized regions of the brainstem40 that regulate the 8 
autonomic control of BP could potentially be such sites. In rodents, neurons in areas including 9 
the nucleus tractus solitarius and rostral ventrolateral medulla (RVLM) are directly sensitive to 10 
hypoxia and cause sympathoexcitation and augmented BP 41 42. Moreover, Marina et al. 13 11 
showed that hypoxia-induced activation of the RVLM in spontaneously hypertensive rats could 12 
be supressed by adenosine triphosphate antagonists or a glycogenesis inhibitor. These data 13 
indicate that metabolic by-products, which are increased during hypoxemia, can activate the 14 
neurons directly controlling sympathetic outflow.  15 
 16 
Exactly what causes elevated cerebral vascular resistance in hypertension is unclear. In the 17 
cerebral circulation, larger arteries predominantly regulate cerebral vascular resistance to blood 18 
flow, rather than the smaller arterioles 43, 44. Alterations in the structure of the large feeder 19 
arteries and collateral vessels are, therefore, likely contributors to increased cerebral vascular 20 
resistance predisposing individuals to hypertension.  For the first time, we present interesting 21 
evidence that the prevalence of congenital cerebral variants confined to the posterior circulation 22 
(VAH and an incomplete posterior CoW) is greater in hypertensive patients compared to 23 
controls. This supports the concept proposed by Dickinson 9, that vertebral artery narrowing  24 
triggers brainstem hypoperfusion and hypertension. We report that hypertensive participants 25 
with VAH (and those with both VAH plus an incomplete posterior CoW) had lower cerebral 26 
perfusion and elevated cerebral vascular resistance. VAH and an incomplete posterior CoW 27 
have both been individually linked to increased risk of posterior territory stroke 45 46 and may 28 
provide an explanation as to why hypertension is a specific risk factor for posterior circulation 29 
infarcts 47. We show that VAH is linked to a higher proportion of lacunar type infarcts in our 30 
cohort of hypertensive patients. Additionally, congenital variants in the cerebral circulation may 31 
help to explain a proportion of the estimated inheritance of hypertension (30-68% 4). However, if 32 
these variants are indeed congenital, then it is perplexing why hypertension develops with age 33 
rather than during childhood development. Potentially, VAH and/or an incomplete posterior CoW 34 
might predispose individuals to cerebrovascular disease, since these smaller vessels may be 35 
prone to pro-thrombotic/atherosclerotic damage, increasing the risk of stenosis or occlusion in 36 
the hypoplastic vessel15. However, this needs further research. Intriguingly, we show that 37 
normotensive patients who exhibit these anatomical variants do not have elevated cerebral 38 
vascular resistance, and have a normal cerebral perfusion suggesting adequate remodelling 39 
has compensated.   Exactly what prevents an increase in cerebral vascular resistance in these 40 
patients is unclear but may include: compensation from the other vertebral artery, collateral 41 
vessel formation to maintain cerebral perfusion and/or lower rates of cerebral atherosclerotic 42 
disease. The exact mechanism(s) might provide therapeutic insight. 43 
 44 
In hypertensive patients without VAH, cerebral blood flow remained lower than that measured in 45 
aged matched normotensives with normal vertebral anatomy. This might be explained by the 46 
increased incidence of cerebral small vessel disease in hypertension, which may develop before 47 
the onset of high BP 33. Although basal blood flow is important, cerebral vascular reactivity to 48 
changes in metabolic demand are also crucial for cerebral health and is impacted by cerebral 49 
vessel disease. We used a visual task to assess regional changes in cerebral blood flow in 50 
hypertensives and normotensives. Whilst there were no differences in blood flow responses 51 
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between groups in the occipital lobe, the hypertensives had a greater systemic BP response 1 
during the challenge. This suggests that the increased blood flow was driven by the elevation of 2 
BP in the hypertensive group.  These data support our ‘selfish brain hypothesis’: generation of 3 
hypertension to satiate the brain.  4 
 5 
We propose that the level of cerebral arterial resistance could be used as a novel prognostic 6 
indicator of those who will become hypertensive, and might be a valuable diagnostic marker to 7 
stratify treatment. However, a longitudinal study is needed to confirm this. For example, 8 
borderline hypertensive patients with elevated cerebrovascular resistance may benefit from 9 
early treatment with specific anti-hypertensive therapies that prevent further vessel remodelling 10 
and are known to improve cerebral blood flow (e.g. angiotensin converting enzyme inhibitors 48 11 
or angiotensin receptor blockers 35), although this requires further investigation. Future research 12 
focused on screening for hypoplastic vertebral arteries (particularly genetic variants 4) may also 13 
be advantageous to better direct anti-hypertensive treatment, as VAH could add complication in 14 
treating high BP whilst preventing cerebral hypoperfusion and early onset dementia. 15 
 16 
In summary, we show that that congenital cerebrovascular variants in the posterior cerebral 17 
circulation and associated changes in cerebral blood flow and vascular resistance may be a 18 
factor in triggering essential hypertension. Due to the cross-sectional design of this study, 19 
further longitudinal based research is required to confirm that high cerebral vascular resistance 20 
and congenital cerebral vascular variants are causal in the onset of hypertension in humans. 21 
Once this mechanism is confirmed, cerebrovascular architecture should potentially be 22 
considered in the prognosis, diagnosis and treatment of hypertension. Early treatment to 23 
prevent further vascular remodelling might help to prevent both the progression of hypertension 24 
but also vascular dementia. 25 
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Table 1: Characteristics of participants in the case-control study. 1 
 Normotensive (n=49) Hypertensive (n=77) 
Female sex (%) 57  58 
Age (years) 52 ± 2 57 ± 2 
Height (cm) 171 ± 1 172 ± 1 
Weight (kg) 71 ± 2 82 ± 2 
Body mass index (kg/m2) 25.2 ± 0.8 27.7 ± 0.5 *** 
Office                   SBP (mmHg) 
                             DBP 
                             MBP 
                             HR (beats/min) 
122 ± 2 
75 ± 1 
91 ± 1 
65 ± 2 
148 ± 2 **** 
89 ± 2 **** 
109 ± 2 **** 
66 ± 1 
ABPM daytime     SBP (mmHg) 
                             DBP 
                             MBP 
                             HR (beats/min) 
119 ± 2 
76 ± 1 
90 ± 1 
75 ± 2 
139 ± 2 **** 
85 ± 2 **** 
101 ± 2 **** 
74 ± 1 
ABPM night          SBP (mmHg) 
                             DBP 
                             MBP 
                             HR (beats/min) 
107 ± 2 
64 ± 1 
79 ± 1 
65 ± 2 
122 ± 2 **** 
72 ± 1 **** 
89 ± 1 **** 
64 ± 1 
Anti-hypertensive medications (#) 0  1 (0 – 6) 
ACEi (%) 
ARB (%) 
CCB (%) 
Diuretic (%) 
β-blocker (%) 
α-blocker (%) 
I1-blocker (%) 
0 
0 
0 
0 
0 
0 
0 
23 
15 
20 
19 
8 
2 
2 
Family history of hypertension (%) 17  48††† 
Brain volumes 
White matter (%) 
Grey matter (%) 
Grey/white matter ratio 
 
38.61 
40.49 
1.05 
 
38.33 
41.74 ** 
1.09 ** 
Total CBF (ml/min/100 mL tissue) 54.4 ± 1.1 61.8 ± 1.4 **** 
Total CVR (ml/min/100mL/mmHg) 1.91 ± 0.05 1.28 ± 0.03 **** 
SBP; systolic blood pressure, DBP; diastolic BP, MBP; mean blood pressure, HR; heart rate, 2 
ABPM; ambulatory blood pressure monitoring, ACEi; angiotensin converting enzyme inhibitor, 3 
ARB; angiotensin receptor blocker, CCB; calcium channel blocker, CBF; cerebral blood flow, 4 
CVR; cerebral vascular resistance. Family history of hypertension in first order relatives is self-5 
reported. Data are mean ± SEM or median (IQR). *** P<0.001 (unpaired Students T-test), ** 6 
P<0.01 **** P<0.0001 (One-way ANCOVA, BMI as covariate). ††† P<0.001; Fisher’s exact test. 7 
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Table 2: Characteristics of normotensive (NTN) and hypertensive (HTN) sub-groups.  
 Young-NTN 
(n=20) 
Older-NTN 
(n=28) 
Borderline-HTN 
(n=20) 
Untreated-HTN 
(n=20) 
Treated-HTN 
(n=19) 
Uncontrolled-HTN 
(n=18) 
Age (years) 28 ± 0.8 52 ± 2 * 51 ± 3 * 56 ± 2 * 58 ± 2 * 59 ± 2 * 
Sex (% women) 50 50 45 50 55 46 
BMI (kg/m2) 24.0 ± 0.8 24.5 ± 0.6 28.3 ± 1.1 * † 28.0± 1.2 28.7 ± 1.0 *† 31.0 ± 0.9 *† 
Office                   
SBP (mmHg)                   
DBP                           
MBP                         
HR (beats/min) 
 
121 ± 3 
73 ± 2 
89 ± 2 
67 ± 3 
 
123 ± 2 
76 ± 1 
92 ± 1 
64 ± 2 
 
138 ± 2* 
84 ± 2 
103 ± 1 
64 ± 2 
 
169 ± 5 *†‡§ 
99 ± 3*†‡§ 
122 ± 4 *†‡§ 
67 ± 2 
 
138 ± 3 
82 ± 2 
102 ± 2 
68 ± 3 
 
163 ± 5 *†‡§ 
93 ± 2 *†‡§ 
116 ± 3  *†‡§ 
68 ± 3 
ABPM daytime      
SBP (mmHg) 
DBP                       
MBP                         
HR (beats/min) 
 
121 ± 2 
78 ± 2 
90 ± 2 
77 ± 3 
 
118 ± 2 
76 ± 1 
90 ± 1 
74 ± 2 
 
132 ± 2 *† 
82 ± 1† 
97 ± 2*† 
72 ± 2 
 
150 ± 4 *†‡§ 
93 ± 3  *†‡§ 
111 ± 3 *†‡§ 
76 ± 2 
 
127 ± 2  
80 ± 2 
95 ± 1 
76 ± 2 
 
146 ± 2 *†‡§ 
88 ± 2 *†‡§ 
106 ± 2  *†‡§ 
70 ± 3 
ABPM night          
SBP (mmHg)                   
DBP                           
MBP                         
HR (beats/min) 
 
114 ± 3 
66 ± 3 
82 ± 3 
68 ± 4 
 
105 ± 2 
63 ± 1 
78 ± 1 
64 ± 2  
 
118 ± 2*† 
70 ± 2† 
86 ± 2† 
64 ± 2 
 
126 ± 3*†‡§ 
76 ± 2*† 
93 ± 2*† 
65 ± 2 
 
115 ± 2 
70 ± 2 
84 ± 2 
76 ± 2 
 
128 ± 3  *†‡§ 
74 ± 2† 
90 ± 4*† 
63 ± 3 
Anti-hypertensive 
medications (#) 
0 0 0 0 2.0 (1.0-2.0) 3.0 (1.5 – 2.5) 
ACEi (%) 
ARB (%) 
CCB (%) 
Diuretic (%) 
β-blocker (%) 
α-blocker (%) 
I1-blocker (%) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
42 
32 
26 
42 
16 
0 
5 
63 
37 
63 
47 
21 
11 
5 
Family history HTN (%) 5 22 55 † 59 † 58 † 56 † 
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See Table 1 for abbreviations. Data are mean ± SEM or median (IQR). * P<0.05 vs. young-NTN, † P<0.05 vs. older-NTN, ‡P<0.05 vs. 
borderline-HTN, § P<0.05 vs. treated-HTN (One-way ANCOVA with Bonferroni test for multiple comparisons, or chi-square test where 
appropriate).  
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Table 3: Regional (bi-lateral) cerebral perfusion in hypertensive compared to 
normotensive humans included in the case-control study  
Regional perfusion 
(mL/100g/min) 
Hypertension Normotension P-value 
Brainstem  25.7 ± 0.7 29.1 ± 0.9 0.003 
Cerebellum 34.1 ± 1.1 42.2 ± 1.3  <0.0001 
Pons  25.3 ± 0.7 27.9 ± 0.9  0.022 
Medulla 25.9 ± 1.0 22.7 ± 0.7 0.006 
Midbrain 28.9 ± 1.0 34.8 ± 1.3 0.001 
Insula 46.1 ± 1.2  54.4 ± 1.2  <0.0001 
Thalamus 39.6 ± 1.2 46.7 ± 1.2 <0.0001 
Occipital pole 37.3 ± 1.7 50.0 ± 2.1 <0.0001 
Frontal pole 38.1 ± 1.2 45.6 ± 1.5 <0.0001 
Precentral gyrus 37.7 ± 1.1 44.7 ± 1.4 <0.0001 
Anterior cingulate cortex 49.2 ± 1.1 57.2 ± 1.6  <0.0001 
Temporal pole  34.6 ± 1.0 40.6 ± 1.2 <0.0001 
P-values represent one-way analysis of covariance with body mass index as a covariate 
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Figure legends 
Figure 1:  Congenital variants of the posterior cerebral circulation are more 
prevalent in people with hypertension compared to normotensive controls. A and 
B: examples vertebral artery hypoplasia (VAH; right image) and an incomplete posterior 
circle of Willis (iCoW; no posterior communicating arteries; pCoA; right image). C: 
(retrospective study, n=133) prevalence of VAH and iCoW is higher in patients with 
hypertension compared to the prevalence in controls. There were no differences in age 
(51 ± 2 vs. 51 ± 2 years, p=0.93), sex (males; 56% vs. 50%, p=0.50), systolic blood 
pressure (SBP; 169 ± 3 vs. 170.1± 3 mmHg, p=0.87) or diastolic blood pressure (DBP; 
97 ± 2 vs. 96 ± 5 mmHg, p=0.72) between hypertensive patients with VAH and those 
without this anatomical variant. D: (case-control study, n=136) prevalence of VAH and 
VAH with an incomplete posterior CoW in hypertensives and normotensive controls. The 
retrospective study is compared to data previously described by Park et al15. ** P=0.006 
(binary logistic regression), ****P<0.0001 (Fishers exact test). 
 
Figure 2: vertebral artery hypoplasia (VAH) or VAH that co-exists with an 
incomplete circle of Willis (iCoW) are linked with lower cerebral blood flow (CBF) 
and elevated cerebral vascular resistance (CVR). A and B:  total CBF and CVR 
estimated via phase contrast imaging in participants with (n=56) and without (n=68) 
VAH. C and D:  total CBF and CVR in participants with VAH plus an incomplete 
posterior circle of Willis (VAH+iCoW; n=42) or without this anatomical variant (n=82). E 
and F: CBF and CVR in those with/without VAH split in hypertensive (HTN) or 
normotensive (NTN) groups. G and H: similar data to E and F but grouped by incidence 
of VAH+iCoW. Groups with VAH or VAH+iCoW had a higher CVR and a lower CBF 
compared to those without these variants. Data are mean ± SEM. **** P<0.0001 (one-
way ANCOVA with BMI as covariate and Bonferroni for multiple comparisons), * P<0.05, 
***P<0.001 (one-way ANCOVA with BMI as covariate and Bonferroni for multiple 
comparisons). I to L: examples of 3-D blood velocity pixel maps in a cross section of the 
left and right vertebral arteries (LVA; RVA), from a normotensive and hypertensive 
volunteer without VAH (NoVAH) and with VAH (+VAH). Each large square represents a 
time point in the cardiac cycle starting with peak systole. Velocity maps for nine 
successive time points within a cardiac cycle are shown in participants. In these 
examples, a negative velocity (blue to orange) represents blood travelling in a direction 
towards the brain (anterograde flow). Flow velocity is clearly lower in hypoplastic 
vessels, but in hypertensive patients the contralateral vessel does not correct for this as 
it does in normotensive controls.  
 
Figure 3: Cerebral vascular resistance (CVR) is elevated before increased muscle 
sympathetic nerve (MSNA) activity in patients with borderline hypertension. A: 
total CVR and muscle MSNA in young normotensive (yNTN), older NTN (oNTN), 
borderline hypertensive (bHTN), untreated HTN (uHTN), treated but poorly controlled 
HTN (pcHTN) and treated controlled HTN (tHTN) participants. B:  total cerebral blood 
flow (CBF) in the 6 groups. C: examples of multi-unit MSNA recordings in the 6 groups. 
Blue recordings represent integrated bursts of MSNA measured directly from the 
peroneal nerve, which are cardiac synchronous and coupled to the arterial pressure 
waveform shown below in pink. * P<0.05 vs. young NTN, † P<0.05 vs. older NTN (one-
way ANCOVA with BMI as covariate and Bonferroni for multiple comparisons). 
Figure 4: Cerebrovascular reactivity in the visual cortex is maintained in patients 
with hypertension due to a systemic pressor response, which does not occur in 
normotensive controls. A: example BOLD signal change during a visual (flashing 
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checker-board) stimulus in a patient with a normal posterior cerebral circulation (left) and 
patient with vertebral artery hypoplasia (VAH) plus an incomplete posterior circle of Willis 
(iCoW, right). B: average positive and negative BOLD (left), cerebral blood flow   (CBF; 
middle), and mean arterial pressure (MAP; right) responses to visual stimulus (flashing 
checker-board) in participants with normotension and hypertension. There was no 
difference in cerebral reactivity to the visual stimulus in hypertensive and normotensive 
patients; however, the hypertensive group had a greater blood pressure (BP) response 
to the stimulus (ANCOVA, BMI as covariate). C: CBF and BOLD responses to the visual 
stimulus in patients grouped by posterior anatomical variants (those with or without 
VAH+iCoW). Participants with VAH+iCoW had a lower cerebral vascular reactivity (lower 
BOLD signal change) than those without VAH+iCoW. In the VAH+iCoW group there was 
only a trend towards a greater BP response to the visual stimulus (Mann-Whitney test). 
All participants had a negative BOLD and cerebral blood flow response to visual stimulus 
in some brain voxels, which is associated with a blood flow steal to increase flow to more 
metabolic active regions 49. In the hypertensive participants, stealing blood flow from 
tissue that is already hypoperfused may put this tissue at risk of becoming ischemic.  
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Novelty and significance 
What is known?  Cerebral arterial remodelling occurs in humans with hypertension and animal 
models of hypertension.  Experimental animal models of hypertension indicate that cerebral vascular 
remodelling occurs before the onset of hypertension. 
What new information does this article contribute?   Hypertension is more common in people with congenital cerebrovascular 
anatomical variants (i.e. vertebral artery hypoplasia).  These anatomical variants were associated with lower cerebral perfusion, 
especially in hypertensive patients.  Vertebral artery hypoplasia was more prevalent in people with high-normal blood 
pressure (who had an elevated family history of hypertension) compared to a 
normotensive cohort.  A cross sectional study indicated that cerebral hypoperfusion occurs before the 
onset of elevated sympathetic nerve activity and hypertension, and thus may be 
causal in the onset of the disease.  
Summary  
Data from animal models of hypertension indicate that hypertension may develop as a 
vital mechanism to maintain adequate blood flow to the brain. In this study we 
investigated whether this mechanism is involved in the aetiology of human hypertension. 
Using magnetic resonance imaging we reveal that there is a higher prevalence of 
congenital cerebral vascular variants in patients with hypertension compared to healthy 
controls. We found that the majority of hypertensive patients exhibited vertebral artery 
hypoplasia and missing or hypoplastic posterior communicating arteries. This resulted in 
increased cerebrovascular resistance and hypoperfusion of the brain. This novel finding 
became more revealing when, surprisingly; we found that the cerebral artery variants, 
high cerebrovascular resistance and cerebral hypoperfusion were already present in 
patients with high-normal blood pressure (but with a strong family history of 
hypertension). This suggests that they were not caused by high blood pressure and may 
be causal in the development of hypertension. Additionally, untreated hypertensive 
patients had normal cerebral blood flow, but those on treatment (with normal blood 
pressure) had reduced cerebral perfusion. Our data may have novel prognostic and 
diagnostic importance; potentially patients with congenital cerebral hypoplasia are at risk 
of developing hypertension. Moreover, the data caution against aggressive lowering of 
blood pressure without checking cerebral perfusion adequacy. Longitudinal studies are 
needed to confirm this.  
 
 
 
